{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:12:21Z","timestamp":1760908341070},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,1]]},"DOI":"10.1093\/jjco\/hyl075","type":"journal-article","created":{"date-parts":[[2006,8,3]],"date-time":"2006-08-03T20:13:57Z","timestamp":1154636037000},"page":"552-556","source":"Crossref","is-referenced-by-count":23,"title":["Early Phase II Study of Uracil\u2013Tegafur Plus Doxorubicin in Patients with Unresectable Advanced Biliary Tract Cancer"],"prefix":"10.1093","volume":"36","author":[{"given":"Junji","family":"Furuse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Funakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Yamao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michitaka","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Nakachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumasa","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,8,3]]},"reference":[{"key":"key\n\t\t\t\t20171013062428_B1","unstructured":"National Cancer Center. Cancer statistics in Japan 2005. http:\/\/www.ncc.go.jp\/en\/statistics\/index.html (accessed 10 May 2006)."},{"key":"key\n\t\t\t\t20171013062428_B2","unstructured":"Haskell CM, ed. Cancer Treatment. 5th edn. Philadelphia: WB Saunders Co. 2001."},{"key":"key\n\t\t\t\t20171013062428_B3","doi-asserted-by":"crossref","unstructured":"Levin B. Gallbladder carcinoma. Ann Oncol1999;10(Suppl):129\u201330.","DOI":"10.1093\/annonc\/10.suppl_4.S129"},{"key":"key\n\t\t\t\t20171013062428_B4","doi-asserted-by":"crossref","unstructured":"Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol1996;7:593\u2013600.","DOI":"10.1093\/oxfordjournals.annonc.a010676"},{"key":"key\n\t\t\t\t20171013062428_B5","doi-asserted-by":"crossref","unstructured":"Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer1998;34:977\u201386.","DOI":"10.1016\/S0959-8049(97)10166-6"},{"key":"key\n\t\t\t\t20171013062428_B6","doi-asserted-by":"crossref","unstructured":"Davis HL Jr, Ramirez G, Ansfield FJ. Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy. Cancer1974;33:193\u20137.","DOI":"10.1002\/1097-0142(197401)33:1<193::AID-CNCR2820330128>3.0.CO;2-S"},{"key":"key\n\t\t\t\t20171013062428_B7","doi-asserted-by":"crossref","unstructured":"Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer1984;54:965\u20139.","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X"},{"key":"key\n\t\t\t\t20171013062428_B8","doi-asserted-by":"crossref","unstructured":"Patt YZ, Jones DV Jr, Hoque A, Lozano R, Markowitz A, Raijman I, et al. Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol1996;14:2311\u201315.","DOI":"10.1200\/JCO.1996.14.8.2311"},{"key":"key\n\t\t\t\t20171013062428_B9","doi-asserted-by":"crossref","unstructured":"Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol1984;2:1245\u20138.","DOI":"10.1200\/JCO.1984.2.11.1245"},{"key":"key\n\t\t\t\t20171013062428_B10","doi-asserted-by":"crossref","unstructured":"Ellis PA, Norman A, Hill A, O'Brien ME, Nicolson M, Hickish T, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer1995;31A:1594\u20138.","DOI":"10.1016\/0959-8049(95)00323-B"},{"key":"key\n\t\t\t\t20171013062428_B11","doi-asserted-by":"crossref","unstructured":"Morizane C, Okada S, Okusaka T, Ueno H, Saisho T. Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer. Oncology2003;64:475\u20136.","DOI":"10.1159\/000070310"},{"key":"key\n\t\t\t\t20171013062428_B12","doi-asserted-by":"crossref","unstructured":"Ishii H, Furuse J, Yonemoto N, Nagase M, Yoshino M, Sato T. Chemotherapy in the treatment of advanced gallbladder cancer. Oncology2004;66:138\u201342.","DOI":"10.1159\/000077440"},{"key":"key\n\t\t\t\t20171013062428_B13","unstructured":"Fujii S, Ikenaka K, Fukushima M, Shirasaka T. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Jpn J Cancer Res1978;69:763\u201372."},{"key":"key\n\t\t\t\t20171013062428_B14","doi-asserted-by":"crossref","unstructured":"Pazdur R, Lassere Y, Diaz-Canton E, Bready B, Ho DH. Phase I trials of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule-dependent toxicities. Anticancer Drugs1996; 7:728\u201333.","DOI":"10.1097\/00001813-199609000-00002"},{"key":"key\n\t\t\t\t20171013062428_B15","doi-asserted-by":"crossref","unstructured":"Mani S, Sciortino D, Samuels B, Arrietta R, Schilsky RL, Vokes EE, et al. Phase II trial of uracil\/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs1999;17:97\u2013101.","DOI":"10.1023\/A:1006268018519"},{"key":"key\n\t\t\t\t20171013062428_B16","doi-asserted-by":"crossref","unstructured":"Chen JS, Yang TS, Lin YC, Jan YY. A phase II trial of tegafur\u2013uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas. Jpn J Clin Oncol2003;33:353\u20136.","DOI":"10.1093\/jjco\/hyg070"},{"key":"key\n\t\t\t\t20171013062428_B17","doi-asserted-by":"crossref","unstructured":"Ikeda M, Okusaka T, Ueno H, Morizane C, Furuse J, Ishii H. A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma. Jpn J Clin Oncol2005;35:439\u201343.","DOI":"10.1093\/jjco\/hyi131"},{"key":"key\n\t\t\t\t20171013062428_B18","doi-asserted-by":"crossref","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst2000;92:205\u201316.","DOI":"10.1093\/jnci\/92.3.205"},{"key":"key\n\t\t\t\t20171013062428_B19","doi-asserted-by":"crossref","unstructured":"Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol2001;12:183\u20136.","DOI":"10.1023\/A:1008352123009"},{"key":"key\n\t\t\t\t20171013062428_B20","doi-asserted-by":"crossref","unstructured":"Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol2001;12:1403\u20136.","DOI":"10.1023\/A:1012543223020"},{"key":"key\n\t\t\t\t20171013062428_B21","doi-asserted-by":"crossref","unstructured":"Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol2004;15:1339\u201343.","DOI":"10.1093\/annonc\/mdh351"},{"key":"key\n\t\t\t\t20171013062428_B22","doi-asserted-by":"crossref","unstructured":"Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol2004;15:478\u201383.","DOI":"10.1093\/annonc\/mdh096"},{"key":"key\n\t\t\t\t20171013062428_B23","doi-asserted-by":"crossref","unstructured":"Thongprasert S, Napapan S, Charoentum C, Moonprakan S. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol2005;16:279\u201381.","DOI":"10.1093\/annonc\/mdi046"},{"key":"key\n\t\t\t\t20171013062428_B24","doi-asserted-by":"crossref","unstructured":"Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol2005;23:2332\u20138.","DOI":"10.1200\/JCO.2005.51.008"},{"key":"key\n\t\t\t\t20171013062428_B25","doi-asserted-by":"crossref","unstructured":"Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, et al. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmaol2005; 57:647\u201353.","DOI":"10.1007\/s00280-005-0095-3"},{"key":"key\n\t\t\t\t20171013062428_B26","doi-asserted-by":"crossref","unstructured":"Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer2004; 91:1769\u201374.","DOI":"10.1038\/sj.bjc.6602208"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/36\/9\/552\/5115827\/hyl075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T06:29:40Z","timestamp":1507876180000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jjco\/article\/36\/9\/552\/875919\/Early-Phase-II-Study-of-UracilTegafur-Plus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,3]]},"references-count":26,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2006,8,3]]},"published-print":{"date-parts":[[2006,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyl075","relation":{},"ISSN":["1465-3621","0368-2811"],"issn-type":[{"value":"1465-3621","type":"electronic"},{"value":"0368-2811","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,9]]},"published":{"date-parts":[[2006,8,3]]}}}